- Home
- Apac Taxane Market
APAC Taxane Market - Industry Trends and Forecast to 2029
- Published Date: September, 2022 | Report ID: CLS-400 | No of pages: 235 | Format:
Asia-Pacific taxane market is projected to register a substantial CAGR of 8.7% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2022 to 2029.
Market Segmentation:
Asia-Pacific Taxane Market, By Type (Paclitaxel, Docetaxel, Cabazitaxel), Drug Type (Generics, Branded), Formulation (Liposomes, Nanoparticles, Polymeric Micelles, Others), Age Group (Adults, Geriatric), Application (Breast Cancer, Non-Small Lung Cancer, Pancreatic Cancer, Ovarian Cancer, Prostate Cancer, Others), End User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Others) Distribution Channel (Retail Sales, Direct Tender), Country (China, Japan, India, South Korea, Singapore, Thailand, Vietnam, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific) Industry Trends and Forecast to 2029
Some of the major factors contributing to the growth of the Asia-Pacific taxane market are:
The rise in incidence of cancer
The funding by the government and investment in research and development
Market Segmentation:
Asia-Pacific taxane market is categorized into seven notable segment which is type, drug type, formulation, age group, application, end user and distribution channel.
On the basis of type, the Asia-Pacific taxane market is segmented into paclitaxel, docetaxel and cabazitaxel.
On the basis of application, the Asia-Pacific taxane market is segmented into ovarian cancer, breast cancer, prostate cancer, non-small cell lung cancer and other
On the basis of drug type, the Asia-Pacific taxane market is segmented into branded and generics
On the basis of formulation, the Asia-Pacific taxane market is segmented into liposomes, nanoparticles, polymeric micelles and others
On the basis of age group, the Asia-Pacific taxane market is segmented into adults and geriatric
On the basis of end user, the Asia-Pacific taxane market is segmented into hospitals, ambulatory surgical centers, specialty clinics, and others
On the basis of distribution channel, the Asia-Pacific taxane market is segmented into direct tender, retail sales
Market Players:
The key market players for Asia-Pacific taxane market are listed below:
Viatris Inc.
Sandoz International GmbH (A Novartis Division)
sanofi-aventis U.S. LLC
Hikma Pharmaceuticals PLC
Pfizer Inc.
Dr. Reddys Laboratories Ltd.
Taxane Healthcare
Bristol-Myers Squibb Company
Fresenius Kabi AG (Subsidiary of Fresenius SE & Co. KGaA)
SAMYANG HOLDINGS CORPORATION.
Luye Pharma Group
Elevar Therapeutics
Huiang Pharmaceutical Co Ltd.
Shenzhen Main Luck Pharmaceuticals Inc.
Accord Healthcare
Torrent Pharmaceuticals Ltd.
Panacea Biotec
RPG Life Sciences Limited.
Aureate Healthcare
Samarth Life Sciences Pvt. Ltd.
Cipla Inc.
Hetero Healthcare Limited.
Ingenus Pharmaceuticals, LLC
TABLE OF CONTENT
TABLE OF CONTENTS
1 INTRODUCTION 38
1.1 OBJECTIVES OF THE STUDY 38
1.2 MARKET DEFINITION 38
1.3 OVERVIEW OF ASIA PACIFIC TAXANE MARKET 38
1.4 CURRENCY AND PRICING 40
1.5 LIMITATIONS 40
1.6 MARKETS COVERED 41
2 MARKET SEGMENTATION 45
2.1 MARKETS COVERED 45
2.2 GEOGRAPHICAL SCOPE 46
2.3 YEARS CONSIDERED FOR THE STUDY 47
2.4 DBMR TRIPOD DATA VALIDATION MODEL 48
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 51
2.6 MULTIVARIATE MODELLING 52
2.7 MARKET APPLICATION COVERAGE GRID 52
2.8 TYPE LIFELINE CURVE 53
2.9 DBMR MARKET POSITION GRID 54
2.10 VENDOR SHARE ANALYSIS 56
2.11 SECONDARY SOURCES 57
2.12 ASSUMPTIONS 57
3 EXECUTIVE SUMMARY 58
4 PREMIUM INSIGHT 62
4.1 PESTEL_ANALYSIS 63
4.2 PORTER'S FIVE FORCES MODEL 64
5 EPIDEMIOLOGY 65
6 INDUSTRIAL INSIGHTS 66
6.1 CONCLUSION 67
7 ASIA PACIFIC TAXANE MARKET: REGULATIONS 68
8 MARKET OVERVIEW 73
8.1 DRIVERS 75
8.1.1 THE RISE IN INCIDENCE OF CANCER 75
8.1.2 THE FUNDING BY THE GOVERNMENT AND INVESTMENT IN RESEARCH AND DEVELOPMENT 76
8.1.3 RISE IN PIPELINE OR CLINICAL TRIALS OF TAXANE TREATMENTS 76
8.1.4 USE OF REIMBURSEMENT FOR TAXANE 77
8.2 RESTRAINTS 77
8.2.1 SIDE EFFECTS OF DRUGS INCURRED WITH THE TAXANE DRUGS 77
8.2.2 ETHICAL ISSUES RELATED TO THE USE OF TAXANE TREATMENT 78
8.2.3 RISE IN PRODUCT RECALLS 78
8.3 OPPORTUNITIES 79
8.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS 79
8.3.2 RISE IN HEALTHCARE EXPENDITURE 79
8.4 CHALLENGES 80
8.4.1 THE LACK OF SKILLED PROFESSIONALS REQUIRED FOR TAXANE DRUG TREATMENT 80
8.4.2 STRINGENT GOVERNMENT REGULATIONS ON TAXANE DRUG TREATMENT 80
9 ASIA PACIFIC TAXANE MARKET, BY TYPE 82
9.1 OVERVIEW 83
9.2 PACLITAXEL 86
9.2.1 BY TYPE 86
9.2.1.1 SEMI-SYNTHETIC 87
9.2.1.2 NATURAL 87
9.2.2 BY STRENGTH 87
9.2.2.1 100MG 87
9.2.2.2 200MG 87
9.2.2.3 250MG 87
9.2.2.4 30MG 87
9.2.2.5 260MG 87
9.2.2.6 300MG 88
9.3 DOCETAXEL 88
9.3.1 120MG 89
9.3.2 80MG 89
9.3.3 20MG 89
9.3.4 40MG 89
9.3.5 60MG 89
9.4 CABAZITAXEL 89
9.4.1 60MG 90
10 ASIA PACIFIC TAXANE MARKET, BY APPLICATION 91
10.1 OVERVIEW 92
10.2 BREAST CANCER 95
10.3 NON-SMALL CELL LUNG CANCER 95
10.4 PANCREATIC CANCER 96
10.5 OVARIAN CANCER 97
10.6 PROSTATE CANCER 97
10.7 OTHERS 98
11 ASIA PACIFIC TAXANE MARKET, BY DRUG TYPE 99
11.1 OVERVIEW 100
11.2 GENERICS 103
11.3 BRANDED 104
12 ASIA PACIFIC TAXANE MARKET, BY FORMULATION 105
12.1 OVERVIEW 106
12.2 LIPOSOMES 109
12.3 NANOPARTICLES 109
12.4 POLYMERIC MICELLES 110
12.5 OTHERS 111
13 ASIA PACIFIC TAXANE MARKET, BY AGE GROUP 112
13.1 OVERVIEW 113
13.2 ADULT 116
13.2.1 FEMALE 117
13.2.2 MALE 117
13.3 GERIATRIC 117
13.3.1 FEMALE 118
13.3.2 MALE 118
14 ASIA PACIFIC TAXANE MARKET, BY END USER 119
14.1 OVERVIEW 120
14.2 HOSPITALS 123
14.3 AMBULATORY SURGICAL CENTERS 123
14.4 SPECIALTY CLINICS 124
14.5 OTHERS 125
15 ASIA PACIFIC TAXANE MARKET, BY DISTRIBUTION CHANNEL 126
15.1 OVERVIEW 127
15.2 RETAIL SALES 130
15.2.1 HOSPITAL PHARMACY 130
15.2.2 RETAIL PHARMACY 131
15.2.3 ONLINE PHARMACY 131
15.3 DIRECT TENDER 131
16 ASIA PACIFIC TAXANE MARKET, BY REGION 132
16.1 ASIA-PACIFIC 133
16.1.1 CHINA 142
16.1.2 JAPAN 146
16.1.3 INDIA 150
16.1.4 SOUTH KOREA 154
16.1.5 AUSTRALIA 158
16.1.6 INDONESIA 162
16.1.7 THAILAND 166
16.1.8 PHILIPPINES 170
16.1.9 VIETNAM 174
16.1.10 SINGAPORE 178
16.1.11 MALAYSIA 182
16.1.12 REST OF ASIA-PACIFIC 186
17 ASIA PACIFIC TAXANE MARKET: COMPANY LANDSCAPE 187
17.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 187
18 SWOT ANALYSIS 188
19 COMPANY PROFILE 189
19.1 BRISTOL-MYERS SQUIBB COMPANY 189
19.1.1 COMPANY SNAPSHOT 189
19.1.2 REVENUE ANALYSIS 189
19.1.3 COMPANY SHARE ANALYSIS 190
19.1.4 PRODUCT PORTFOLIO 190
19.1.5 RECENT DEVELOPMENTS 190
19.2 SANOFI-AVENTIS U.S. LLC 192
19.2.1 COMPANY SNAPSHOT 192
19.2.2 REVENUE ANALYSIS 192
19.2.3 COMPANY SHARE ANALYSIS 193
19.2.4 PRODUCT PORTFOLIO 193
19.2.5 RECENT DEVELOPMENTS 193
19.3 VIATRIS INC. 195
19.3.1 COMPANY SNAPSHOT 195
19.3.2 REVENUE ANALYSIS 195
19.3.3 COMPANY SHARE ANALYSIS 196
19.3.4 PRODUCT PORTFOLIO 196
19.3.5 RECENT DEVELOPMENT 196
19.4 SANDOZ INTERNATIONAL GMBH (A NOVARTIS DIVISION) 197
19.4.1 COMPANY SNAPSHOT 197
19.4.2 REVENUE ANALYSIS 197
19.4.3 COMPANY SHARE ANALYSIS 198
19.4.4 PRODUCT PORTFOLIO 198
19.4.5 RECENT DEVELOPMENTS 199
19.5 FRESENIUS KABI AG (SUBSIDIARY OF FRESENIUS SE & CO. KGAA ) 200
19.5.1 COMPANY SNAPSHOT 200
19.5.2 REVENUE ANALYSIS 200
19.5.3 COMPANY SHARE ANALYSIS 201
19.5.4 PRODUCT PORTFOLIO 201
19.5.5 RECENT DEVELOPMENTS 201
19.6 HIKMA PHARMACEUTICALS PLC 203
19.6.1 COMPANY SNAPSHOT 203
19.6.2 REVENUE ANALYSIS 203
19.6.3 PRODUCT PORTFOLIO 204
19.6.4 RECENT DEVELOPMENTS 204
19.7 ACCORD HEALTHCARE 205
19.7.1 COMPANY SNAPSHOT 205
19.7.2 PRODUCT PORTFOLIO 205
19.7.3 RECENT DEVELOPMENTS 205
19.8 AQVIDA GMBH 206
19.8.1 COMPANY SNAPSHOT 206
19.8.2 PRODUCT PORTFOLIO 206
19.8.3 RECENT DEVELOPMENTS 206
19.9 AUREATE HEALTHCARE 207
19.9.1 COMPANY SNAPSHOT 207
19.9.2 PRODUCT PORTFOLIO 207
19.9.3 RECENT DEVELOPMENTS 207
19.10 CIPLA INC. 208
19.10.1 COMPANY SNAPSHOT 208
19.10.2 REVENUE ANALYSIS 208
19.10.3 PRODUCT PORTFOLIO 209
19.10.4 RECENT DEVELOPMENTS 209
19.11 DR. REDDYS LABORATORIES LTD. 210
19.11.1 COMPANY SNAPSHOT 210
19.11.2 REVENUE ANALYSIS 210
19.11.3 PRODUCT PORTFOLIO 211
19.11.4 RECENT DEVELOPMENTS 211
19.12 ELEVAR THERAPEUTICS 212
19.12.1 COMPANY SNAPSHOT 212
19.12.2 PRODUCT PORTFOLIO 212
19.12.3 RECENT DEVELOPMENTS 212
19.13 HETERO HEALTHCARE LIMITED. 214
19.13.1 COMPANY SNAPSHOT 214
19.13.2 PRODUCT PORTFOLIO 214
19.13.3 RECENT DEVELOPMENTS 214
19.14 HUIANG PHARMACEUTICAL CO LTD 215
19.14.1 COMPANY SNAPSHOT 215
19.14.2 PRODUCT PORTFOLIO 215
19.14.3 RECENT DEVELOPMENTS 215
19.15 INGENUS PHARMACEUTICALS, LLC 216
19.15.1 COMPANY SNAPSHOT 216
19.15.2 PRODUCT PORTFOLIO 216
19.15.3 RECENT DEVELOPMENTS 216
19.16 LUYE PHARMA GROUP 217
19.16.1 COMPANY SNAPSHOT 217
19.16.2 REVENUE ANALYSIS 217
19.16.3 PRODUCT PORTFOLIO 218
19.16.4 RECENT DEVELOPMENTS 218
19.17 PANACEA BIOTEC 219
19.17.1 COMPANY SNAPSHOT 219
19.17.2 REVENUE ANALYSIS 219
19.17.3 PRODUCT PORTFOLIO 220
19.17.4 RECENT DEVELOPMENTS 220
19.18 PFIZER INC. 221
19.18.1 COMPANY SNAPSHOT 221
19.18.2 REVENUE ANALYSIS 221
19.18.3 PRODUCT PORTFOLIO 222
19.18.4 RECENT DEVELOPMENTS 222
19.19 RPG LIFE SCIENCES LIMITED 223
19.19.1 COMPANY SNAPSHOT 223
19.19.2 REVENUE ANALYSIS 223
19.19.3 PRODUCT PORTFOLIO 224
19.19.4 RECENT DEVELOPMENTS 224
19.20 SAMARTH LIFE SCIENCES PVT. LTD. 225
19.20.1 COMPANY SNAPSHOT 225
19.20.2 PRODUCT PORTFOLIO 225
19.20.3 RECENT DEVELOPMENTS 225
19.21 SAMYANG HOLDINGS CORPORATION. 226
19.21.1 COMPANY SNAPSHOT 226
19.21.2 REVENUE ANALYSIS 226
19.21.3 PRODUCT PORTFOLIO 227
19.21.4 RECENT DEVELOPMENTS 227
19.22 SHENZHEN MAIN LUCK PHAR MACEUTICALS INC. 228
19.22.1 COMPANY SNAPSHOT 228
19.22.2 PRODUCT PORTFOLIO 228
19.22.3 RECENT DEVELOPMENTS 228
19.23 TORRENT PHARMACEUTICALS LTD 229
19.23.1 COMPANY SNAPSHOT 229
19.23.2 REVENUE ANALYSIS 229
19.23.3 PRODUCT PORTFOLIO 230
19.23.4 RECENT DEVELOPMENTS 230
19.24 TAXANE HEALTHCARE 231
19.24.1 COMPANY SNAPSHOT 231
19.24.2 PRODUCT PORTFOLIO 231
19.24.3 RECENT DEVELOPMENTS 231
20 QUESTIONNAIRE 232
21 RELATED REPORTS 235
Segmentation
Short Description
Asia-Pacific Taxane Market, By Type (Paclitaxel, Docetaxel, Cabazitaxel), Drug Type (Generics, Branded), Formulation (Liposomes, Nanoparticles, Polymeric Micelles, Others), Age Group (Adults, Geriatric), Application (Breast Cancer, Non-Small Lung Cancer, Pancreatic Cancer, Ovarian Cancer, Prostate Cancer, Others), End User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Others) Distribution Channel (Retail Sales, Direct Tender), Country (China, Japan, India, South Korea, Singapore, Thailand, Vietnam, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific) Industry Trends and Forecast to 2029
Market Definition:
The taxanes or taxoids are a closely related group of antineoplastic agents that have a unique mechanism of action as inhibitors of mitosis and which are widely used in the therapy of ovarian, breast, lung, esophageal, prostate, bladder and head and neck cancers. Three taxanes are in clinical use, paclitaxel (Taxol: 1992), docetaxel (Taxotere: 1996) and cabazitaxel (Jevtana: 2010). Taxanes are anticancer drugs that interfere with microtubule function, causing changes in mitosis and cellular death. Paclitaxel (Taxol) was first isolated from a yew tree, a small evergreen coniferous tree with a slow growth rate. As paclitaxel was initially scarce, docetaxel (Taxotere), a semisynthetic analogue of paclitaxel derived from the needles of the European yew tree Taxus baccata, was created. Docetaxel differs from paclitaxel in two chemical locations, making it more water soluble. Lung cancer, prostate cancer, squamous cell carcinoma of the head and neck, breast cancer, Kaposi's sarcoma, gastric cancer, bladder cancer, esophageal cancer and other carcinomas are all commonly treated with paclitaxel and docetaxel. Cabazitaxel is also a semisynthetic analogue of natural taxoids and was developed for its lack of affinity for P-glycoprotein, a common mediator of docetaxel resistance.
Market Segmentation:
The Asia-Pacific taxane market is categorized into seven notable segments which are based type, drug type, formulation, age group, application, end user and distribution channel.
On the basis of type, the Asia-Pacific taxane market is segmented into paclitaxel, docetaxel and cabazitaxel
On the basis of drug type, the Asia-Pacific taxane market is segmented into branded and generics
On the basis of formulation, the Asia-Pacific taxane market is segmented into liposomes, nanoparticles, polymeric micelles, others
On the basis of age group, the Asia-Pacific taxane market is segmented into adults and geriatric
On the basis of application, the Asia-Pacific taxane market is segmented into ovarian cancer, breast cancer, prostate cancer, pancreatic cancer, non-small cell lung cancer and others
On the basis of end user, the Asia-Pacific taxane market is segmented into hospitals, ambulatory surgical centers, specialty clinics, and others
On the basis of distribution channel, the Asia-Pacific taxane market is segmented into direct tender, retail sales
Market Players
Some of the major players operating in the Asia-Pacific taxane market are:
Viatris Inc.
Sandoz International GmbH (A Novartis Division)
sanofi-aventis U.S. LLC
Hikma Pharmaceuticals PLC
Pfizer Inc.
Dr. Reddys Laboratories Ltd.
Taxane Healthcare
Bristol-Myers Squibb Company
Fresenius Kabi AG (Subsidiary of Fresenius SE & Co. KGaA)
SAMYANG HOLDINGS CORPORATION.
Luye Pharma Group
Elevar Therapeutics
Huiang Pharmaceutical Co Ltd.
Shenzhen Main Luck Pharmaceuticals Inc.
Accord Healthcare
Torrent Pharmaceuticals Ltd.
Panacea Biotec
RPG Life Sciences Limited.
Aureate Healthcare
Samarth Life Sciences Pvt. Ltd.
Cipla Inc.
Hetero Healthcare Limited.
Ingenus Pharmaceuticals, LLC
Methodology
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.